Zobrazeno 1 - 10
of 352
pro vyhledávání: '"James R. Jett"'
Autor:
Gerard A. Silvestri, James R. Jett
Publikováno v:
Journal of Clinical Oncology. 41:2141-2143
Autor:
Pierre P. Massion, Yu Shyr, Karel G.M. Moons, John A. Worrell, David P. Carbone, Eric L. Grogan, Steve Deppen, Carol Callaway-Lane, Joe B. Putnam, James R. Jett, Aaron Bungum, Ciara Calitri, Rama Rajanbabu, Xueqiong J. Zhang, Ming Li, Chad V. Pecot
Background: Current management of lung nodules is complicated by nontherapeutic resections and missed chances for cure. We hypothesized that a serum proteomic signature may add diagnostic information beyond that provided by combined clinical and radi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6342c785c8aa4dc4855946f6ed23d9d1
https://doi.org/10.1158/1055-9965.c.6515967.v1
https://doi.org/10.1158/1055-9965.c.6515967.v1
Autor:
Pierre P. Massion, Yu Shyr, Karel G.M. Moons, John A. Worrell, David P. Carbone, Eric L. Grogan, Steve Deppen, Carol Callaway-Lane, Joe B. Putnam, James R. Jett, Aaron Bungum, Ciara Calitri, Rama Rajanbabu, Xueqiong J. Zhang, Ming Li, Chad V. Pecot
PDF file - 252K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690ed8db438b0d4f9a4b2b591e05d45b
https://doi.org/10.1158/1055-9965.22437609
https://doi.org/10.1158/1055-9965.22437609
Autor:
Jennifer King, Upal Basu Roy, M. Patricia Rivera, Bruce E. Johnson, Adam H. Fox, James R. Jett, Nikki A. Martin, Raymond U. Osarogiagbon, Lauren S. Rosenthal, Gerard A. Silvestri, Robert A. Smith
Publikováno v:
Chest
BACKGROUND: Targeted therapies for advanced non-small cell lung cancer (NSCLC) with oncogenic drivers have caused a paradigm shift in care. Biomarker testing is needed to assess eligibility for these therapies. Pulmonologists often perform bronchosco
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0197826 (2018)
OBJECTIVE:Patients who have incidentally detected pulmonary nodules and an estimated intermediate risk (5-60%) of lung cancer frequently are followed via computed tomography (CT) surveillance to detect nodule growth, despite guidelines for a more agg
Externí odkaz:
https://doaj.org/article/81e3f326e613438b8d00d81799d36eb5
Autor:
Gerard A. Silvestri, Anil Vachani, Alex Porter, Nichole T. Tanner, James R. Jett, Steven C. Springmeyer, Peter J. Mazzone
Publikováno v:
Chest. 159:1283-1287
Autor:
Nicole Martin, Robert A. Smith, Gerard A. Silvestri, Jennifer L. Ersek, James R. Jett, Renato G. Martins, Edward S. Kim, Jennifer King, Upal Basu Roy, Amy Moore
Publikováno v:
Journal of Thoracic Oncology. 14:338-342
Autor:
James R. Jett, Steven C. Springmeyer
Publikováno v:
Journal of Bronchology & Interventional Pulmonology
Autor:
Nichole T, Tanner, Steven C, Springmeyer, Alex, Porter, James R, Jett, Peter, Mazzone, Anil, Vachani, Gerard A, Silvestri
Publikováno v:
Chest. 159(3)
Autor:
Egbert F. Smit, Thomas E. Stinchcombe, James R. Jett, David R. Gandara, David R. Spigel, Martin Reck, Fred R. Hirsch, Suresh S. Ramalingam, Ronald B. Natale, Mark A. Socinski, Edward S. Kim, Craig H. Reynolds, Corey J. Langer, Heather A. Wakelee, Jeffrey D. Bradley, Philip Bonomi, Luis Paz-Ares, Silvia Novello, Keith M. Kerr, Maurice Pérol, Nick Thatcher, Coleman K. Obasaju, Johan Vansteenkiste, Paul A. Bunn
Publikováno v:
Hirsch, F R, Kerr, K M, Bunn, P A, Kim, E S, Obasaju, C, Pérol, M, Bonomi, P, Bradley, J D, Gandara, D, Jett, J R, Langer, C J, Natale, R B, Novello, S, Paz-Ares, L, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Stinchcombe, T E, Vansteenkiste, J F, Wakelee, H & Thatcher, N 2018, ' Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer : Effect of Current and Future Therapies and Technologies ', Clinical Lung Cancer, vol. 19, no. 4, pp. 331-339 . https://doi.org/10.1016/j.cllc.2018.03.014, https://doi.org/10.1016/j.cllc.2018.03.014
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is